Table 3. Baseline and operative of patients with and without Parkinson’s disease who underwent spinal deformity surgery.
| Variables | Control (n=10,878) | Parkinson’s disease (n=165) | P value |
|---|---|---|---|
| Age, mean ± SD (years) | 59±15 | 69±8 | <0.001* |
| Age >65 years (%) | 37.9 | 66.7 | <0.001* |
| Male gender (%) | 26.7 | 47.3 | <0.001* |
| Race (%) | 0.494 | ||
| Caucasian | 91.4 | 95.2 | |
| African American | 3.3 | <6.7 | |
| Hispanic and other | 5.3 | <6.7 | |
| Primary payer (%) | <0.001* | ||
| Medicare | 44.7 | 72.1 | |
| Medicaid | 3.8 | <6.7 | |
| Private insurance | 47.3 | 26.7 | |
| Other | 4.2 | <6.7 | |
| CCI score, median (IQR) | 0 (0–1) | 0 (0–1) | 0.646 |
| Osteoporosis (%) | 8.7 | 12.1 | 0.125 |
| Complex procedure (%) | 31.3 | 36.4 | 0.162 |
| Cervical spine fusion (%) | 6.7 | 6.7 | 0.993 |
| Thoracic fusion (%) | 45.1 | 48.5 | 0.382 |
| Lumbosacral fusion (%) | 66.7 | 71.5 | 0.194 |
| Use of rh-BMP-2 (%) | 39.4 | 43.0 | 0.349 |
| RBC transfusion (%) | 27.6 | 30.9 | 0.346 |
*, statistical significance. SD, standard deviation; CCI, Charlson Comorbidity Index; IQR, interquartile range; rh-BMP-2, recombinant human bone morphogenetic protein-2; RBC, red blood cell.